WHO Criteria (1979)

Measure the sum of the products of diameters (SPD), bidimensional 

Complete Response: tumor not detected for at least 4 weeks

Partial Response: ≥50% reduction in the SPD from baseline also confirmed at 4 weeks

 Progressive Disease: ≥25% increase in tumor size in one or more lesions

Stable Disease: Neither partial response nor progressive disease 

Source:

WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979

RECIST 1.0 (2000)

Measure the longest dimension, minimum size = 10mm at spiral CT, 20mm at conventional CT

Ten target lesions measured, 5 per organ

Complete Response: Disappearance of all lesions for >4 weeks

Progressive Disease: ≥ 20% increase from nadir

Partial Response: ≥ 30% decrease from baseline 

Stable Disease: Neither partial response nor progressive disease 

Source:

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16

RECIST 1.1 (2009)

Measure the sum of longest diameters (SOD) except in lymph nodes

Lymph nodes short axis: target lesions ≥15mm, non-target lesions = 10-15mm, non-pathological lesions < 10mm

Measure five target lesions (2 per organ); minimum size = 10mm

Complete Response: Disappearance of all target lesions for >4 weeks, any pathological lymph nodes (target or non-target) reduction in sort axis to <10mm

Partial Response: At least 30% decrease in the SOD

Progressive Disease: >20% increase in the SOD

Stable Disease: Neither partial response nor progressive disease

Source:

Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombeand J. Verweij (2009). "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)." European Journal of Cancer 45(2): 228-247

Immune-Related RECIST (iRECIST)

Modification of RECIST v1.1

Measure the longest diameter, minimum size = 10mm, except for lymph node

Lymph node short axis, minim size = 15mm

Measure five target lesions (2 pre organ); minimum size = 10mm

Complete Response: Disappearance of all lesions, and all nodes < 10mm

Partial Response: ≥30% decrease from baseline

Progressive Disease: ≥20% increase from the nadir

Stable Disease: Neither partial response nor progressive disease 

Source:

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013). Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(14), 3936–3943. doi:10.1158/1078-0432.CCR-13-0895

Immune-Related Response Criteria (irRC)

Measure the sum of the products of diameters (SPD), minimum size = 5mm x 5mm, bidimensional

Ten target lesions measured, 5 per organ

Complete Response: Disappearance of all lesions

Partial Response: ≥50% decrease from baseline

Progressive Disease: ≥25% increase from the nadir 

Source:

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013). Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clinical cancer research : an official journal of the American Association for Cancer Research, 19(14), 3936–3943. doi:10.1158/1078-0432.CCR-13-0895